Dren Bio
PrivateLast Round
Early Funding
Oct 29, 2026
Est. Valuation
$306M
Total Funding Raised
$506M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Dren Bio is a biotechnology company that develops therapeutic antibodies designed to selectively target and deplete pathogenic cells and disease-causing agents for the treatment of cancer, autoimmune disorders, and other serious diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Dren Bio Comparables
Compare Dren Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| LTZ Therapeutics | 84% | |
| Electra Therapeutics | 84% | |
| Abcuro | 82% |
Dren Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Oct 29, 2026 | ||||
| Strategic | Jul 24, 2024 | ||||
| Series B | Jun 14, 2022 | ||||
| Series A | Oct 16, 2020 | ||||
| Seed | Jul 1, 2019 |
Dren Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Cormorant Asset Management | Early Funding |
| Taiho Ventures | Series B, Early Funding, Series A |
| OrbiMed | Early Funding |
| Juvia Group | Early Funding |
| ArrowMark Partners | Series B, Early Funding |
| General Catalyst | Early Funding |
| HBM Healthcare Investments | Early Funding, Series A, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 29, 2026
$350M round led by Lightspeed Venture Partners and Juvia Group.
- Apr 1, 2026
Launched proprietary platform for developing multispecific antibodies.
Recent news
Latest coverage and updates
- is_developingOct 30, 2026
In Jul '24, Dren Bio, Inc. partners with Novartis Pharma, a Novartis subsidiary, to discover and develop therapeutic bispecific antibodies to treat cancer.
- receives_financingOct 29, 2026
On Oct 29th '26 in California, Dren Bio, Inc. receives an oversubscribed $350M private financing co-led by Juvia Group and Lightspeed Venture Partners to support late-stage clinical development, regulatory submission, and the planned commercial launch of dibotatug.
Dren Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Dren Bio's valuation, stock price, and market status.
Is Dren Bio a public or private company?
Dren Bio is a private company.
What is the current stock price of Dren Bio?
Dren Bio is a private company, so its shares have no public market price. Caplight tracks Dren Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Dren Bio worth (valuation)?
Dren Bio's valuation is estimated at $306.0M based on funding round data.
Can I buy Dren Bio stock?
Dren Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Dren Bio's last funding round?
Dren Bio's most recent funding round was Early Funding on October 29, 2026.
Who are the main investors in Dren Bio?
Key investors in Dren Bio include Taiho Ventures, Juvia Group, HBM Healthcare Investments, Aisling Capital, 8VC.
Will Dren Bio IPO soon?
No public IPO plans have been announced for Dren Bio.
How can I track Dren Bio secondary market activity?
Caplight tracks bids, offers, and trades in Dren Bio's shares on secondary markets.